- Home
- BARK vs KZIA Comparison
BARK vs KZIA Comparison
Compare BARK & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BARK | KZIA |
|---|---|---|
| Founded | 2011 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.7M | 100.8M |
| IPO Year | N/A | 2002 |
Fundamental Metrics
Financial Performance| Metric | BARK | KZIA |
|---|---|---|
| Price | $9.60 | $13.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $37.50 | $19.50 |
| AVG Volume (30 Days) | 89.7K | ★ 192.6K |
| Earning Date | 06-03-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.43 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $4.86 |
| 52 Week High | $11.00 | $17.40 |
Technical Indicators
Market Signals| Indicator | BARK | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 56.05 | 58.83 |
| Support Level | $8.25 | $5.62 |
| Resistance Level | $10.40 | $14.57 |
| Average True Range (ATR) | 0.89 | 1.10 |
| MACD | -0.07 | 0.22 |
| Stochastic Oscillator | 69.51 | 74.66 |
Price Performance
Historical ComparisonAbout BARK BARK Inc.
BARK Inc is a vertically integrated, omnichannel brand serving dogs across two key categories: toys & accessories and consumables. It serves dogs nationwide with monthly subscription services, BarkBox and Super Chewer; e-commerce experience on BarkShop.com; custom collections via its retail partner network, including Target and Amazon; wellness products that meet dogs' needs with BARK Bright; and a personalized meal delivery service for dogs BARK Eats. The company's reportable segments are; Direct to Consumer (D2C), and Commerce. The majority of its revenue is generated from the Direct to Consumer segment which derives revenue from the sale of toys & accessories and consumables through BarkBox, Super Chewer, and the company's consumables website.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.